Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Alnylam Pharmaceuticals (ALNY) is trading at $235.60, down 4.51% on the day. Its market value of $31.53B makes it the 427th largest of the 800 companies we follow.
Over the past 52 weeks it has traded between $197.81 and $495.55, so it sits 52.5% below the top of that range.
In the quarter ended Jun 2026 the company brought in $1.29B of revenue, up 66.9% from a year earlier, with $164.49M of net profit (a 16.1% margin).
Buyers are paying 41.0 times trailing earnings, 125% above its five-year average of 18.2. The median for its industry group is 33.2.
21 analysts follow the stock and the average call is "buy". The mean target, $369.96, sits 57.0% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 800 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Trading closer to its 52-week high than most peers scores higher.
21 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
ALNY is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-07-06, the strategy has returned 1524.8% (321.7% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $369.96, 57.0% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $299.00, so shares trade 21.2% below that estimate. On earnings multiple, it sits in the 84th percentile of its own five-year valuation range (pricier than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Quote as of Oct 1, 2026 12:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 800 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 41.0x earnings, ALNY looks expensive against the market, and trades 24% above the 33.2x median among Biotechnology names. The two comparisons do not always agree.
$235.60 is the latest print for ALNY, a move of -4.51% against yesterday's close of $246.74. Today's low and high so far: $233.53 and $251.71.
Equity value comes to $31.53B at the current price. By that measure it is number 427 of the 800 names in our coverage.
Buyers pay 41.0 times the last twelve months of profit (EPS $2.33). Averaged over five years the multiple has been 18.2, and today's level ranks in the 84th percentile of its own history.
The year's floor is $197.81 and the ceiling $495.55. Shares are 52.5% away from that ceiling.
Our data shows no dividend paid by Alnylam Pharmaceuticals over the trailing twelve months.
Of 21 analysts, 86% say buy, 14% hold and 0% sell. Price targets average $369.96, with the most cautious at $230.00 and the most optimistic at $489.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on ALNY.